Delivery Order SPE2DB20D1109-SPE2DB24FN99E
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $10,714.94 for the supply of RINVOQ ER 15 MG TABLET products. The award was made by the Defense Logistics Agency (DLA) Troop Support Medical, a major healthcare provider for the Department of Defense. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $28,639.87 from the Defense Logistics Agency (DLA). The contract is for the provision of RINVOQ ER 15 MG TABLET, a pharmaceutical product, with a performance period through November 2024. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order worth $12,143.49 for the supply of RINVOQ ER 30 MG TABLET UU 30S medical products. The contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a Defense agency, on December 21, 2023, with an ultimate completion date of December 22, 2023. The contract is a Firm Fixed Price arrangement. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of pharmaceutical products and medical supplies, including the prescription drug RINVOQ ER 45 MG TABLET. The award, valued at $9,030.57, was made by the Defense Logistics Agency (DLA) Troop Support Medical, which is part of the U.S. Department of Defense. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order with a ceiling value of $24,219.52 for the supply of RINVOQ ER 15 MG TABLET. The contract was awarded on December 12, 2022 by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of December 13, 2022. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $17,211.95 for the supply of 4562967074 ! RINVOQ ER 15 MG TABLET UU 30S. The contract has an ultimate completion date of December 4, 2023 and was awarded on December 1, 2023. The contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a major supplier of pharmaceutical products and medical supplies to the Department of Defense and other federal...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (DO) under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The DO, valued at $29,597.45, is for the delivery of the pharmaceutical product RINVOQ ER 15 MG TABLET. The IDC, valued at up to $999,999,999, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of the drug Rinvoq ER 15 mg tablet. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $9,016.67 and a completion date of February 6, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., with the Defense Logistics Agency (DLA) Troop Support Medical. The delivery order, valued at $8,923.10, is for the pharmaceutical product RINVOQ ER 15 MG TABLET. The broader IDC with the DLA Troop Support Medical is valued at up to $999,999,999.00 and runs through November 2026, enabling Amerisourcebergen to efficiently deliver a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of pharmaceutical products. The award, valued at $17,908.87, is a firm fixed-price delivery order with a completion date of February 13, 2024. The contract covers the delivery of RINVOQ ER 15 MG TABLET, a prescription medication, and does not have a set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB24FN99EDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of a pharmaceutical product, RINVOQ ER 15 MG TABLET, to the Defense Logistics Agency (DLA). The contract, valued at $24,147.11, is a firm-fixed-price delivery order with an ultimate completion date of April 16, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.1k | 4/15/24 |